{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T12:29:27Z","timestamp":1793795367744,"version":"4.6.1"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 4","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Bullous pemphigoid (BP) is the most common autoimmune blistering disease in older adults and is increasingly associated with dipeptidyl peptidase-4 (DPP-4) inhibitors used in type 2 diabetes mellitus. Sitagliptin-associated BP is uncommon and may be complicated by secondary infections and multisystem involvement. A 74-year-old female with type 2 diabetes mellitus and hypertension presented with generalized weakness, burning micturition, abdominal pain, painful blistering skin lesions, and oral erosions. She had been receiving sitagliptin 100 mg once daily for approximately 2 years before symptom onset. Skin biopsy demonstrated a subepidermal bulla with eosinophilic infiltrates, suggestive of BP. Sitagliptin was discontinued after admission. The hospital course was complicated by bilateral pyelonephritis with multidrug-resistant urosepsis requiring bilateral double-J stenting, oral candidiasis caused by\n                    <jats:italic toggle=\"yes\">Candida albicans<\/jats:italic>\n                    , recurrent gastrointestinal bleeding, and tubulovillous adenoma with high-grade dysplasia. Persistent dermatologic disease with markedly elevated immunoglobulin E levels necessitated omalizumab therapy, resulting in gradual improvement. Sitagliptin-associated BP should be considered in elderly diabetic patients presenting with blistering disorders after prolonged gliptin exposure. Early diagnosis, withdrawal of the suspected drug, histopathological confirmation, and multidisciplinary management are essential for favorable outcomes.\n                  <\/jats:p>","DOI":"10.4103\/aam.aam_676_26","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:00:10Z","timestamp":1786374010000},"page":"S884-S887","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Sitagliptin-associated Bullous Pemphigoid Complicated by Secondary Candidiasis, Urosepsis, and Gastrointestinal Bleeding in an Elderly Diabetic Woman"],"prefix":"10.4103","volume":"25","author":[{"given":"Lavalik","family":"Boppana","sequence":"first","affiliation":[{"name":"Department of General Medicine, Bharati Vidyapeeth Deemed University Medical College, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya Salil","family":"Barsode","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Bharati Vidyapeeth Deemed University Medical College, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vatsav","family":"Mandava","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Apollo Institute of Medical Sciences and Research, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kritika","family":"Dadhia","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Bharati Vidyapeeth Deemed University Medical College, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"R1-20261104","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"R2-20261104","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.clindermatol.2011.03.005","article-title":"Bullous pemphigoid: From the clinic to the bench","volume":"30","author":"Di Zenzo","year":"2012","journal-title":"Clin Dermatol"},{"key":"R3-20261104","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jaad.2017.12.038","article-title":"Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland","volume":"78","author":"Benzaquen","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R4-20261104","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jamadermatol.2018.2352","article-title":"Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients","volume":"154","author":"Kridin","year":"2018","journal-title":"JAMA Dermatol"},{"key":"R5-20261104","doi-asserted-by":"crossref","first-page":"adv00224","DOI":"10.2340\/00015555-3457","article-title":"A Systematic Review of Drug-associated Bullous Pemphigoid","volume":"100","author":"Verheyden","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"R6-20261104","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamadermatol.2018.4556","article-title":"Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol"},{"key":"R7-20261104","first-page":"30","article-title":"A Review of Drug-associated Bullous Pemphigoid","volume":"13","author":"Aouidad","year":"2020","journal-title":"J Clin Aesthet Dermatol"},{"key":"R8-20261104","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/jdv.12366","article-title":"Drug-induced pemphigoid: A review of the literature","volume":"28","author":"Stavropoulos","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R10-20261104","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R11-20261104","doi-asserted-by":"crossref","first-page":"212527","DOI":"10.7573\/dic.212527","article-title":"How to manage Pseudomonas aeruginosa infections","volume":"7","author":"Bassetti","year":"2018","journal-title":"Drugs Context"},{"key":"R12-20261104","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","article-title":"Colorectal cancer","volume":"394","author":"Dekker","year":"2019","journal-title":"Lancet"},{"key":"R13-20261104","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40257-018-0401-6","article-title":"Rituximab and omalizumab for the treatment of bullous pemphigoid: A systematic review of the literature","volume":"20","author":"Kremer","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"R14-20261104","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1001\/archdermatol.2012.1604","article-title":"Successful treatment of bullous pemphigoid with omalizumab","volume":"148","author":"London","year":"2012","journal-title":"Arch Dermatol"},{"key":"R15-20261104","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jaad.2014.04.053","article-title":"Omalizumab therapy for bullous pemphigoid","volume":"71","author":"Yu","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"R16-20261104","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.3389\/fimmu.2019.01506","article-title":"New Insights Into the Pathogenesis of Bullous Pemphigoid: 2019 Update","volume":"10","author":"Genovese","year":"2019","journal-title":"Front Immunol"},{"key":"R17-20261104","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev-pathol-012615-044313","article-title":"Mechanisms of disease: Pemphigus and bullous pemphigoid","volume":"11","author":"Hammers","year":"2016","journal-title":"Annu Rev Pathol"},{"key":"R18-20261104","first-page":"90","article-title":"Bullous pemphigoid and malignancy: Myth or reality?","volume":"31","author":"Lucariello","year":"2013","journal-title":"Clin Dermatol"}],"container-title":["Annals of African Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_676_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T12:04:47Z","timestamp":1793793887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_676_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":17,"journal-issue":{"issue":"Suppl 4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/aam.aam_676_26","relation":{},"ISSN":["1596-3519","0975-5764"],"issn-type":[{"value":"1596-3519","type":"print"},{"value":"0975-5764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"2026-05-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}